[Federal Register Volume 61, Number 194 (Friday, October 4, 1996)]
[Notices]
[Page 52034]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 96-25481]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
Advisory Committee Meeting; Amendment of Notice
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing an
amendment to the notice of a joint meeting of the Nonprescription Drugs
Advisory Committee and the Pulmonary-Allergy Drugs Advisory Committee,
which is scheduled for October 10 and 11, 1996. This meeting was
announced in the Federal Register of September 24, 1996 (61 FR 50031 at
50032). The amendment is being made to announce the cancellation of the
entire session on October 11, 1996. There are no other changes. This
amendment will be announced at the beginning of the open portion of the
meeting.
FOR FURTHER INFORMATION CONTACT: Kennerly K. Chapman or Leander B.
Madoo, Center for Drug Evaluation and Research (HFD-21), Food and Drug
Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-443-5455,
or FDA Advisory Committee Information Hotline, 1-800-741-8138 (301-443-
0572 in the Washington, DC area), Nonprescription Drugs Advisory
Committee, code 12541.
SUPPLEMENTARY INFORMATION: In the Federal Register of September 24,
1996, FDA announced that a joint meeting of the Nonprescription Drugs
Advisory Committee and the Pulmonary-Allergy Drugs Advisory Committee
would be held on October 10 and 11, 1996.
On page 50032, in the third column, the agenda for this meeting is
amended as follows:
Date, time, and place. October 10, 1996, 8:30 a.m., Holiday Inn--
Bethesda, Versailles Ballroom, 8120 Wisconsin Ave., Bethesda, MD.
Type of meeting and contact person. Open public hearing, October
10, 1996, 8:30 a.m. to 9:30.m., unless public participation does not
last that long; open committee discussion, 9:30 a.m. to 5 p.m.
Open committee discussion. On October 10, 1996, the committees will
jointly consider new drug application (NDA) 20-463, Nasalcrom
(Cromolyn Sodium Nasal Solution, USP) for over-the-counter (OTC)
treatment of seasonal allergic rhinitis sponsored by McNeil Consumer
Products Co.
Dated: September 27, 1996.
Michael A. Friedman,
Deputy Commissioner for Operations.
[FR Doc. 96-25481 Filed 10-3-96; 8:45 am]
BILLING CODE 4160-01-F
